Ocugen, Inc.
OCGNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeOcugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company carries a $463.8M market cap, placing it firmly in the small-cap category. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.
Market Cap
$463.8M
Beta
2.31
P/E (TTM)
—
P/E (Fwd)
-5.83
EPS (TTM)
$-0.24
EPS (Fwd)
$-0.23
ROE
-660.0%
ROA
-68.2%
Cash
$31.9M
Total Debt
$33.3M
Free CF
-$33.7M
52W Change
60.8%
Annual Financials
Cash vs Debt
The company holds $31.9M in cash, though total debt stands at $33.3M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$33.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -660.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $2.5M (2022) to $4.4M (2025), reflecting a 77% increase over the period.
A beta of 2.31 means OCGN is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Ocugen, Inc.'s trajectory.